NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO launches Brivaracetam tablets, in India, for treatment of epilepsy26-02-2021
26-02-2021
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
copy of news paper publications15-02-2021
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor presentation for the quarter and nine months ended December 31, 202015-02-2021
Earnings Call for Q3FY21 Natco Pharma Ltd.
Conference Call with Natco Pharma Ltd. Management and Analysts on Q3FY21 Performance and Outlook. Listen to the full earnings transcript.12-02-2021
NATCO PHARMA LTD. - 524816 - Board declares Third Interim Dividend
Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 11, 2021, inter alia, has declared 3rd interim dividend of Rs. 1/- (Rupees one only) each per Equity share of Rs. 2/- (Rupees two only) each for the financial. year 2020-21 (which is 50% on the nominal value of the equity share).11-02-2021
NATCO PHARMA LTD. - 524816 - Record Date For Payment Of Interim Dividend
23rd February, 2021 fixed as Record Date for payment of Interim Dividend11-02-2021
NATCO PHARMA LTD. - 524816 - Un Audited Financial Results For The Quarter And Nine Months Ended 31St December, 2020 Along With Press Release
Un audited Financial Results for the quarter and nine months ended 31st December, 2020 along with press release11-02-2021
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q3FY21 Financial Results Earnings Call on Friday, February 12, 2021, at 11:00 AM08-02-2021
Natco Pharma gets registration approval from CIBRC for Chlorantraniliprole
Natco would be the first indigenous manufacturer of this technical product, the company added.05-02-2021